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ABSTRACT
Diabetic nephropathy is the leading cause of ESRD in high-income countries and a growing problem across
the world. Vascular endothelial growth factor-A (VEGF-A) is thought to be a critical mediator of vascular
dysfunction in diabetic nephropathy, yet VEGF-A knockout and overexpression of angiogenic VEGF-A
isoforms each worsen diabetic nephropathy. We examined the vasculoprotective effects of the VEGF-A
isoform VEGF-A165b in diabetic nephropathy. Renal expression of VEGF-A165b mRNA was upregulated in
diabetic individuals with well preserved kidney function, but not in those with progressive disease. Repro-
ducing this VEGF-A165b upregulation in mouse podocytes in vivo prevented functional and histologic
abnormalities in diabetic nephropathy. Biweekly systemic injections of recombinant human VEGF-A165b
reduced features of diabetic nephropathywhen initiated during early or advanced nephropathy in amodel
of type 1 diabetes and when initiated during early nephropathy in amodel of type 2 diabetes. VEGF-A165b
normalized glomerular permeability through phosphorylation of VEGF receptor 2 in glomerular endothe-
lial cells, and reversed diabetes-induced damage to the glomerular endothelial glycocalyx. VEGF-A165b
also improved the permeability function of isolated diabetic human glomeruli. These results show that
VEGF-A165b acts via the endothelium to protect blood vessels and ameliorate diabetic nephropathy.
J Am Soc Nephrol 26: ccc–ccc, 2015. doi: 10.1681/ASN.2014040350
Diabetes is the leading cause of ESRD in the industri-
alized world,1 is the leading cause of blindness in the
working-age population,2 and diabetic nephropathy
eventually affects up to 50% of patients with long-
standing diabetes.3Microvascular dysfunction contrib-
utes to the development and progression of each of
these complications, with abnormal vascular hemody-
namics and disturbed vascular permeability leading
to clinically important excessive vessel leak, such as
macular edema and albuminuria.4
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In recent years, there has been increasing interest in identi-
fying factors that are endogenously produced within the vas-
culature, are activated or inhibited in diabetes, and therefore
could protect against diabetic vasculopathy5 and potentially be
used alongside traditional treatments. These factors, such as
activated protein C,6 modify the response of the vasculature to
the environment, thereby protecting endothelial and other vas-
cular cells from the diabetic milieu. Vascular endothelial growth
factor-A (VEGF-A), a family of secreted glycoprotein isoforms,
has been suggested as such an endogenous protective factor.5,7
VEGF-A levels are dysregulated and VEGF-A receptor pathways
activated in many dysfunctional vascular beds in diabetes.5 In
glomeruli, VEGF-A is predominantly produced by podocytes,
and its actions on endothelial cells and podocytes have been
described.8,9 Targeted, inducible genetic deletion of all VEGF-A
isoforms from podocytes causes glomerular disease in healthy
animals,10 and accelerated nephropathy in diabetic animals.7
Total glomerular VEGF-A levels decrease as diabetic nephrop-
athy progresses in humans,11 and anti–VEGF-A antibodies in-
duce proteinuria in humans.10 VEGF-A is therefore considered
to provide an endogenous “protective” signal that prevents ap-
optosis of vascular wall cells and hence progression of diabetic
nephropathy.
However, upregulating speciﬁc VEGF-A isoforms, such as
VEGF-A165a, can also accelerate diabetic nephropathy.12
VEGF-A165a is a potent vasoactive agent, increasing vasodila-
tion, vascular permeability, and angiogenesis,13 processes that
can drive the adverse functional consequences of diabetic vas-
culopathy. An equilibrium between sufﬁcient (protective) and
excessive (damaging) levels of VEGF-A, or an appropriately
timed VEGF-A response, may underlie this paradox. An alter-
native explanation, however, is that these protective and del-
eterious VEGF-A actions in diabetes could be speciﬁc to
VEGF-A isoforms, wherein some VEGF-A isoforms (e.g.,
VEGF-A164a) are detrimental and others confer protection.14,15
An alternative VEGF-A isoform, VEGF-A165b, confers beneﬁt in
other microvascular disease states.16–18 We therefore tested the
hypothesis that VEGF-A165b could act as a protective factor in
diabetic nephropathy.
RESULTS
VEGF-A165b Is Upregulated in Humans with Diabetic
Nephropathy and Well Preserved Kidney Function
In 12 patients with biopsy-conﬁrmed diabetic glomerulosclero-
sis, expression of exon 5/7/8-containing VEGF-A isoform
(i.e., VEGF-A165a+VEGF-A165b) mRNA was signiﬁcantly re-
duced compared with ﬁndings in ﬁve nondiabetic individuals
(11.964.2 versus 80.0642.3 pg/mg mRNA; P,0.05, unpaired
t test). When diabetic nephropathy was categorized as “early”
with well preserved kidney function and low-grade proteinuria
(creatinine, 8968mmol/L; proteinuria, 1.060.3 g/L; n=5; Sup-
plemental Table 1) or “late” with elevated creatinine and heavy
proteinuria (serum creatinine, 242610 mmol/L; proteinuria,
7.860.2g/L; n=7; Supplemental Table 1), clear differences in the
expression of different VEGF isoforms were apparent (Figure 1).
Total VEGF-A165a+VEGF-A165b mRNA expression progressively
declined from “early” to “late” diabetic nephropathy, primarily
because of decreased VEGF-A165a mRNA levels (Figure 1, A and
B). However, while VEGF-A165b levels also decreased in “late”
diabetic nephropathy (Figure 1C),VEGF-A165b levels signiﬁcantly
increased approximately 6-fold in “early” diabetic nephropathy.
Thus, only those with “early” diabetic nephropathy exhibited an
approximately 12-fold increase in VEGF-A165b as a proportion
of total VEGF-A isoforms present in the kidney (Figure 1D).
Similar changeswereobserved in just theglomerular compartment
(Figure 1E) and at the protein level (Figure 1F). On the basis of
these observations, we hypothesized that increasing glomerular
VEGF-A165b protects against diabetic nephropathy.
Podocyte-Speciﬁc VEGF-A165b Overexpression
Protects Against Diabetic Nephropathy
Streptozotocin (STZ)-induced diabetic wild-type and podocyte-
speciﬁc VEGF-A165b–overexpressing mice (nephVEGF-A165b)
(Figure 2A) demonstrated equivalent hyperglycemia (Figure
2B). Albuminuria increased 10.8-fold in diabetic wild-type
mice but only 2.2-fold in diabetic nephVEGF-A165b mice, a
change that was not statistically signiﬁcantly different from ﬁnd-
ings in nondiabetic controls (Figure 2C). The early diabetes-
related rise in creatinine clearance in diabetic wild-type mice
was also attenuated in diabetic nephVEGF-A165b mice (Figure
2D). After 6 weeks of diabetes, VEGF-A165b–overexpressing
mice also demonstrated less glomerular hypertrophy (Figure 2,
E and F), less mesangial matrix expansion (Figure 2, G and H),
and less glomerular basement membrane thickening (Figure 2,
I and J).
Given that podocyte-speciﬁc overexpression of murine
VEGF-A164a (podVEGF-A164a) accelerates diabetic nephropathy19
and that nephVEGF-A165b overexpression can block inducible
podVEGF-A164a–overexpression permeability changes in healthy
mice,20 we hypothesized that nephVEGF-A165b effects would be
sufﬁciently robust to prevent the more aggressive form of ne-
phropathy in diabetic podVEGF-A164a mice. Wild-type, single-
and double-transgenic nephVEGF-A165b/podVEGF-A164a mice
(Figure 3A) all demonstrated equal hyperglycemia 5 weeks after
streptozotocin. Albuminuria increased an additional 3-fold above
diabetic wild-type littermate values after 1 week of VEGF-A165a
induction in diabetic podVEGF-A164a mice, an effect completely
blocked by co-overexpression of VEGF-A165a with VEGF-A165b
(Figure 3B).
Systemic Injections of VEGF-A165b Protect against
Diabetic Nephropathy
Systemic injections of recombinant human VEGF-A165b pro-
tein (rhVEGF-A165b) reduce angiogenesis-related cancer
growth in mice without altering BP or renal function or elicit-
ing adverse effects.21 We therefore assessed the efﬁcacy of
systemic rhVEGF-A165b injections in STZ-induced diabetes in
DBA2J mice before and after the onset of diabetic nephropathy
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(Figure 4A). After 2 weeks of consistent hyperglycemia, low-
dose 0.04mg/kg rhVEGF-A165b injections were initiated and
continued until an approved study endpoint occurred (signif-
icant weight loss). Equivalent blood glucose concentrations
were observed in both treatment groups (Figure 4B). rh
VEGF-A165b injections consistently reduced urinary albumin-
to-creatinine ratios in diabetic mice, and this effect persisted
throughout the entire period of hyperglycemia (Figure 4C).
In a separate cohort of diabetic DBA2Jmice, low-dose (0.04
mg/kg) or high-dose (0.2 mg/kg) systemic rhVEGF-A165b in-
jections were initiated only after the onset of heavy albuminuria
(12 weeks after STZ administration) (Figure 4D). Notably, al-
buminuria in these different cohort of mice receiving systemic
injectionswas 5–20-fold greater than in the above groups. Again,
vehicle- and rhVEGF-A165b–treated diabeticmice had equivalent
blood glucose concentrations. Urinary albumin-to-creatinine
ratios continued to rise in vehicle-treated diabetic DBA2J mice
(Figure4E).Despitehaving thehighesturine albumin-to-creatinine
ratios at the start of rhVEGF-A165b treatment, albuminuria did not
increase inmice receiving 0.04mg/kg rhVEGF-A165b injections, and
albuminuria decreased in mice receiving 0.2 mg/kg rhVEGF-A165b
(Figure 4, E and F). The rhVEGF-A165b–induced improvements
in albuminuriawere signiﬁcant at both treatmentdoses (Figure4F).
rhVEGF-A165b injections also improved diabetes-induced glo-
merular basement membrane thickening (Figure 4, G and H)
but not mesangial matrix expansion.
Systemic Injections of VEGF-A165b Improve Early
Albuminuria but Not GFR in a Type 2 Diabetic
Nephropathy Model
The global increase in diabetic nephropathy is predominantly
due to type 2 diabetes. We therefore administered an 8-week
round of systemic rhVEGF-A165b injections to obese db/db
mice after the onset of hyperglycemia but before the onset of
albuminuria or decreased GFR (Figure 5A). rhVEGF-A165b
injections (0.2 mg/kg) did not alter blood glucose or body
weight (Figure 5B) but signiﬁcantly reduced albuminuria
(P,0.05) (Figure 5C). Despite this improvement in albumin-
uria, however, rhVEGF-A165b injections did not prevent the
diabetes-related decline in creatinine clearance (Figure 5D) in
these mice. As in the type 1 diabetes model, we also assessed
the efﬁcacy of rhVEGF-A165b injections started after the onset
Figure 1. VEGF-A165b is upregulated in humans with early diabetic nephropathy and well preserved kidney function. (A) mRNA ex-
pression of exon 5/7/8 containing VEGF-A isoforms (i.e., those coding for 165 amino-acid proteins) determined by RT-qPCR relative to
total RNA extracted in whole renal cortical tissue from kidneys unsuitable for transplantation from deceased donors without diabetes
(“none”), donors with early diabetic nephropathy with well preserved kidney function (“early”), and kidney biopsy specimens from
patients with diabetes and advanced nephropathy (“late”) (note logarithmic scale). (B) VEGF-A165a mRNA expression (note logarithmic
scale). (C) VEGF-A165b expression (note logarithmic scale). (D) VEGF-A isoform expression ratio calculated as VEGF-A165b mRNA per
unit total mRNA divided by VEGF-A165a mRNA per unit total mRNA. (E) Ratio of VEGF-A165a to VEGF-A165b mRNA in control and early
diabetic samples in which it was possible to analyze mRNA from single glomeruli isolated by differential sieving. (F) Isoform-speciﬁc
VEGF-A165b protein determined by ELISA as a proportion of total VEGF-A in whole kidney cortical tissue in kidney donors with diabetes
and early nephropathy (“early”) and those without diabetes (“none”). Error bars, SEM. Multiple comparisons: one-way ANOVA. Two-
group comparisons: unpaired t test. *P,0.05; **P,0.01; ***P,0.005, throughout.
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Figure 2. Podocyte-speciﬁc overexpression of VEGF-A165b ameliorates STZ-induced diabetic nephropathy. (A) Transgenic mice consti-
tutively overexpressing human VEGF-A165b in podocytes under control of the nephrin promoter (blue; nephhVEGF-A165b) received in-
jections of STZ or vehicle at 12 weeks of age. Plasma glucose (B), urine albumin-to-creatine ratio (C), and creatinine clearance (D) measured
in nondiabetic wild-type, diabetic wild-type, nondiabetic transgenic, and diabetic transgenic mice 6 weeks after diabetes induction. n=5–10
mice per group. Error bars, SEM. *P,0.05, one-way ANOVA. (E and F) Glomerular area assessed in hematoxylin and eosin–stained kidney
sections from 21 to 55 glomeruli from 3 mice per group. Scale bars: 20 mm. Error bars, SEM. *P,0.05, one-way ANOVA. (G and H) Periodic
acid Schiff–stained kidney sections from each group of mice. Mesangial matrix expansion (arrows) measured as a proportion of total
glomerular area in 45–60 glomeruli from 3 to 4 mice per group. Scale bars: 20 mm. Error bars, SEM. *P,0.05, one-way ANOVA. (I) Low- and
high-magniﬁcation electron micrographs (scale bars: 1 mm and 250 nm, respectively) of glomerular capillaries and the glomerular capillary
wall (GCW) from each group of mice. CL, capillary lumen; ec, endothelial cell; gbm, glomerular basement membrane; pfp, podocyte foot
process; rbc, red blood cell; US, urinary space. (J) Glomerular basement membrane width calculated from 20 to 60 measurements in 8–16
glomerular capillaries per group. Error bars, SEM. *P,0.05, one-way ANOVA.
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of both albuminuria and decreased creatinine clearance (Figure
5E). Albuminuria did not progress in these db/db mice after this
time (Figure 5F), and rhVEGF-A165b injections initiated at this later
time point did not modify the pattern of albuminuria (Figure 5F),
prevent further loss of GFR (Figure 5G), or decrease mesangial
matrix expansion (Figure 5H).
VEGF-A165b Acts via VEGFR-2 to Modify Glomerular
Endothelium
Both podocytes and endothelial cells play important roles in
the progression of diabetic nephropathy. Human podocytes
exhibited substantial apoptosis when cultured in high
glucose–containing medium, a response partially rescued by
rhVEGF-A165b (Figure 6A). Human endothelial cells also dem-
onstrated signiﬁcant apoptosis in response to hyperglycemia,
and rhVEGF-A165b completely blocked the hyperglycemia-
induced endothelial cell apoptosis (Figure 6, B and C). The
pan-VEGFR tyrosine kinase inhibitor PTK787 (Figure 6C)
prevented the antiapoptotic effects of rhVEGF-A165b on hyper-
glycemic endothelial cells.
To determine the functional signiﬁcance of this VEGF-
A165b-VEGFR-2 signaling, we measured glomerular water
permeability in healthy and diabetic rat glomeruli in the
presence of VEGF-receptor inhibitors (Figure 6D). Single
glomeruli harvested from diabetic rat kidneys had higher
volume-corrected glomerular ultraﬁltration coefﬁcient
(LPA/Vi) than glomeruli fromnondiabetic rats; this was normal-
ized by blockade of all VEGF receptors (VEGFRs) with PTK787,
not just by blockade of VEGFR-2 with ZM323881, indicating
that multiple VEGFRs contribute to glomerular permeability
defects in diabetes. In keeping with effects in the intact animal,
this diabetes-induced glomerular permeability change was re-
versed by rhVEGF-A165b. This normalization by
rhVEGF-A165b
was completely blocked by the pan-VEGF-receptor inhibitor
PTK787 and also blocked by the selective VEGFR-2 inhibitor
ZM323881, indicating a key role for VEGFR-2 in diabetic ne-
phropathy in mediating these beneﬁcial effects of VEGF-A165b.
Immunoﬂuorescence studies demonstrated increased total
and phosphorylated forms of VEGFR-2 in the glomeruli of both
nephhVEGF-A165b–overexpressing mice (Figure 6, E and G),
and more robustly in the glomeruli of STZ-induced diabetic
mice treated with systemic rhVEGF-A165b injections (Figure 6,
F andH). These latter ﬁndings conﬁrm that systemic injections
of VEGF-A165b had direct effects on VEGF-signaling pathways
within glomerular cells. In keeping with previous transgenic
studies,9 and dominant antiapoptotic effects of VEGF-A165b on
endothelial cells, upregulated VEGFR-2 in nephhVEGF-A165b-
overexpressing mice co-localized with platelet-endothelial cell
adhesion molecule (PECAM-1) in glomerular endothelial cells
(Figure 7, A and B), but not with nephrin (Figure 7, C and D).
Thus, the dominant actions of acute incubation, local overexpres-
sion, and systemic treatment with VEGF-A165b appear to involve
phosphorylation of VEGFR-2 in the glomerular endothelium.
VEGF-A165b Restores Glomerular Endothelial
Glycocalyx in Diabetic Nephropathy
VEGF-A165b–induced VEGFR-2 activation in the glomerular
endothelium raises the question of how glomerular endothelial
modiﬁcations could restorenormal glomerular function indiabetes.
Electron micrographs (Figure 8A) revealed decreased glomerular
endothelial fenestration in STZ-injected diabetic vehicle-treated
DBA2J mice, but this was not reversed by rhVEGF-A165b treatment
Figure 3. Podocyte-speciﬁc overexpression of VEGF-A165b reduces albuminuria in the dual insult of VEGF-A164a overexpression and
STZ-induced diabetic nephropathy. (A) Heterozygous mice overexpressing human VEGF-A165b in podocytes (blue: nephhVEGF-A165b)
were crossed with mice in which murine VEGF-A164a (mVEGF-A164a) overexpression in podocytes could be induced with doxycycline
(dox): heterozygous podocin-rtTA:TetO-mVEGF-A164a mice (red: pod-TetO-mVEGF-A164a), to generate mice co-overexpressing
mVEGF-A164a and hVEGF-A165b in podocytes. Offspring were treated with STZ at 12 weeks of age to induce diabetes in all groups.
After 5 weeks of diabetes, all mice received doxycycline, inducing mVEGF-A164a overexpression in the two groups carrying the
podocin-rtTA:TetO-mVEGF-A164a transgene. After 1 week of doxycycline treatment, urinary albumin-to-creatine ratio (uACR) was measured
and compared with uACR obtained before doxycycline administration. (B) Change in uACR after 7 days of doxycycline treatment in diabetic
mice with no transgenes, diabetic mice overexpressing hVEGF-A165b alone, diabetic mice overexpressing mVEGF-A164a alone, and diabetic
mice co-overexpressing mVEGF-A164a and hVEGF-A165b. Dashed line represents no change in albuminuria during the 1-week doxycycline
treatment period. n=3–6 mice per group. Error bars, SEM. *P,0.05, one-way ANOVA.
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Figure 4. Systemic treatment with VEGF-A165b blocks progression of albuminuria and glomerular basement membrane thickening in
STZ-induced diabetic nephropathy. (A) Diabetes was induced in wild-type DBA2J mice with STZ injection (nondiabetic control mice
received buffer injection alone). After 2 consecutive weeks of hyperglycemia, mice received an 11-week course of biweekly in-
traperitoneal injections (blue arrows) of recombinant human VEGF-A165b (rhVEGF-A165b) (n=16) or vehicle (n=16). (B) Plasma glucose
measured repeatedly in nondiabetic control, diabetic vehicle-treated, and 0.04 mg/kg rhVEGF-A165b–treated mice. *P,0.05 versus
both diabetic groups; "ns" indicates P.0.05 between diabetic groups; one-way ANOVA for both. (C) Urine albumin-to-creatinine ratio
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(Figure 8B). Direct imaging of the glomerular endothelial
glycocalyx (Figure8A)demonstrated a50%reduction in glycocalyx
depth in vehicle-treated diabetic mice (P,0.05) (Figure 8C).
In keeping with the observed improvements in albuminuria,
rhVEGF-A165b injections restored glomerular endothelial
glycocalyx depth in diabetic mice to levels observed in healthy
nondiabetic control animals (Figure 8C). Loss of endothelial
glycocalyx in diabetes and restoration by rhVEGF-A165b was
conﬁrmed by confocal imaging of viable, unﬁxed glomeruli in
STZ-injected diabetic rats (Figure 9).
VEGF-A165b Improves Human Diabetic Glomerular
Function
Animal models of diabetic nephropathy exhibit substantial
differences from human disease. The functional beneﬁts of
VEGF-A165b observed in multiple diabetic animal models
were therefore tested on diabetic human glomeruli as well.
In humans, rats, and mice, LPA/Vi was signiﬁcantly higher
in glomeruli harvested from diabetic kidneys (all P,0.05
versus nondiabetic controls) (Figure 10A). In addition, long-
term podocyte-speciﬁc overexpression of hVEGF-A165b (mice)
or acute incubation with rhVEGF-A165b (rats and humans) re-
versed this diabetes-related increase in glomerular permeability
(all P,0.05 versus vehicle-incubated diabetic glomeruli) and
restored glomerular permeability to levels observed in non-
diabetic controls (Figure 10A). In paired measurements of
diabetic human glomeruli permeability before and after ex-
posure to rhVEGF-A165b, incubation with
rhVEGF-A165b also
reduced glomerular LPA/Vi to normal values (Figure 10B).
DISCUSSION
We show here that increasing VEGF-A165b levels effectively
improves several functional and histologic features of diabetic
nephropathy. It can do so locally (through podocyte-speciﬁc
overexpression) and systemically (via repeated intraperitoneal
injections). It can do so in the context of additional upregu-
lation of VEGF-A164a and in nephropathy-complicating
models of both type 1 and type 2 diabetes, and it can do so
both before and after the onset of albuminuria. We further
demonstrate that VEGF-A165b acts on glomerular permeability
through VEGFR-2 in glomerular endothelial cells and reverses
diabetes-induced damage to the glomerular endothelial
glycocalyx. We also demonstrate changes in the balance of
VEGF-Axxxa/VEGF-Axxxb isoforms in human diabetic ne-
phropathy, show that glomerular permeability is increased
in diabetic human glomeruli, and show that the direct effects
of VEGF-A165b on the glomerular capillary wall observed in
animal models of diabetic nephropathy are reproduced at a
functional level in diabetic human glomeruli. Thus, it appears
that VEGF-A165b can provide the endogenous protective
actions of VEGF-A in diabetic nephropathy, without driving
the deleterious consequences that appear to be mediated via
VEGF-A165a in diabetic nephropathy.
Despite improved control of systemic parameters in diabetes,
such as hyperglycemia, hypertension, and hyperlipidemia,
diabetic nephropathy remains the leading cause of ESRD
across the developed world and no speciﬁc treatment for
diabetic nephropathy is available.1 Recent developments
have focused on harnessing endogenous vasculoprotective
factors that could provide additional and complementary
beneﬁts for patients with diabetes.5 VEGF-A has long been
considered a critical component of the vascular complications of
diabetes. VEGF-A is generated as two families of isoforms ac-
cording to alternative splicing of the terminal exon, exon 8.22
The canonical, proangiogenic isoforms, such as VEGF-A165a
(VEGF-A164a in the mouse), are matched by a family of an-
tagonistic isoforms (e.g., VEGF-A165b, generically termed
VEGF-Axxxb, where xxx is the number of amino acids they
encode). These VEGF-Axxxb isoforms match the prosurvival
and antiapoptotic effects of angiogenic VEGF-A isoforms but
do not drive angiogenesis, do not cause sustained increases in
permeability, do not cause vasodilatation, and can prevent the
angiogenic and pro-permeability effects of VEGF-A165a.20,23
VEGF-A164a is not an endogenous renoprotective factor in
diabetes because overexpressing VEGF-A164a in diabetic
mice accelerates nephropathy.19 Our studies demonstrate
that the VEGF-A165b isoform confers beneﬁt in diabetic ne-
phropathy. This clariﬁes the previous paradox that both VEGF
overexpression and depletion are detrimental in diabetic ne-
phropathy. It is therefore not just a timely and appropriate level
of total VEGF-A that regulates glomerular and kidney function
in diabetic nephropathy but an appropriate balance of isoforms,
and speciﬁcally sufﬁcient levels of the protective VEGF-A165b
isoform.
This demonstration that VEGF-A165b is a protective iso-
form in kidney disease is consistent with a series of reports that
(uACR) was measured repeatedly in diabetic DBA2J mice receiving injections of vehicle (n=4) or 0.04 mg/kg rhVEGF-A165b (n=4) for up to
11 weeks. *P,0.05, paired t test. (D) Diabetes was induced in wild-type DBA2J mice with STZ injection and vehicle or rhVEGF-A165b
treatment after the onset of albuminuria. (E) uACRmeasured repeatedly inmice receiving biweekly injections of vehicle (n=10), 0.04mg/kg
rhVEGF-A165b (n=10), and 0.2 mg/kg rhVEGF-A165b (n=6) before organ harvest. Error bars, SEM. (F) Fold change in uACR (uACR at in-
dicated time points, divided by uACR before initiation of treatment [arrow]). Dashed line represents no change in albuminuria after start
of injections. Error bars, SEM. *P,0.05, two-way ANOVA. (G) Low- and high-magniﬁcation electron micrographs (scale bars: 1 mm and
500 nm, respectively) of glomerular capillaries and the glomerular capillary wall (GCW). CL, capillary lumen; ec, endothelial cell; gbm,
glomerular basement membrane; pfp, podocyte foot process; rbc, red blood cell; US, urinary space. (H) Glomerular basement membrane
(GBM) width measurements in indicated groups of diabetic mice. Error bars, SEM. *P,0.05, one-way ANOVA.
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Figure 5. Systemic treatment with VEGF-A165b blocks early albuminuria but not later features of diabetic nephropathy in a genetic model of
type 2 diabetic nephropathy. (A) After the onset of hyperglycemia at 6 or 7 weeks of age, db/db mice received biweekly intraperitoneal
injections of recombinant human VEGF-A165b (rhVEGF-A165b) or vehicle (blue arrows) for 8 weeks. (B) Blood glucose measurements in 6 lean
and 20 db/db mice before and after receipt of twice-weekly vehicle or rhVEGF-A165b (0.2 mg/kg) injections. Dashed line indicates start of
intraperitoneal injections. Error bars, SEM. *P,0.05 compared with both groups of diabetic mice; "ns" indicates P.0.05 between groups of
diabetic mice. (C) Urinary albumin-to-creatinine ratio (uACR) determined repeatedly during the 8-week treatment period, divided by uACR
in the same animal before treatment (“baseline”) to calculate fold change in uACR. Dashed line represents no fold change in albuminuria
since start of treatment. Error bars, SEM. *P,0.05, paired t test. (D) Creatinine clearance measured at the end of the 8-week injection
period. Error bars, SEM. *P,0.05; "ns" indicates P.0.05; one-way ANOVA for both. (E) In a separate cohort of older mice, 5 weeks of
biweekly intraperitoneal injections (blue arrows) of rhVEGF-A165b or vehicle were initiated in 14-week-old lean controls (n=5) and db/db mice
(n=14) with long-standing hyperglycemia, established albuminuria, and decreased GFR. (F) Serial measurement of uACR in these older
vehicle- and rhVEGF-A165b–treated db/db mice. Dashed line indicates start of intraperitoneal injections. Error bars, SEM. *P,0.05, paired
t test. (G) At the end of the 5-week injection period, GFR measurements in these older vehicle- and rhVEGF-A165b–treated db/db and lean
mice. Error bars, SEM. *P,0.05; "ns" indicates P.0.05; one-way ANOVA for both. (H) At the end of the 5-week injection period, mesangial
matrix expansion (arrows) in periodic acid Schiff–stained kidney sections from each group of mice. Scale bar: 50 mm.
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nonspeciﬁc inhibition of all VEGF isoforms, for example
with anti-VEGF antibodies, results in proteinuria and overt
renal disease.10 Such strategies will deplete both VEGF-A iso-
form families, thereby removing the protective actions of
VEGF-A165b from the glomerular capillary wall and eliciting
renal dysfunction and disease. Similar isoform-speciﬁc beneﬁts
of VEGF-A165b have also been reported in systemic sclerosis17
and Denys-Drash syndrome,18 ocular disease,16,24 and cancer.25
We show here that diabetic patients with well preserved kid-
ney function have increased VEGF-A165b levels relative to
VEGF-A165a. Transgenic podocyte-speciﬁc VEGF-A165b
overexpression is the most analogous experimental model
of this human situation, and it is noteworthy that the local
upregulation of VEGF-A165b was the most effective approach
in preventing multiple physiologic and histologic changes of
diabetic nephropathy.We hypothesize that patients capable of
upregulating VEGF-A165b relative to VEGF-A165a, via the
modiﬁable machinery that regulates alternative splicing of
the VEGF-A gene,23,26–29 may be protected from progressive
nephropathy in diabetes. How to manipulate this alternative
splicing mechanism for therapeutic beneﬁt requires further
exploration.
VEGFR-2 mediates the major actions of VEGF-A family
members, is indispensable for normal glomerular function,9
and mediates the beneﬁcial effects of VEGF-A165b observed
here. VEGF-A165b and VEGF-A165a bind VEGFR-2 with equal
afﬁnity but elicit different tyrosine residue phosphorylation
patterns, different VEGFR-2/neuropilin-1 heterodimerization
patterns,30,31 and different downstream signaling pathways,30
resulting in different migration, proliferation, and cytoprotec-
tion behaviors in endothelial (and other) cell types.22,24,31 The
observation that selective VEGFR-2 blockade in diabetic animals
worsened albuminuria and endothelial cell apoptosis32 is con-
sistent with blocking beneﬁcial endogenous VEGF-A165b signal-
ing in rodents. Despite appropriate positive controls, however,
the coding sequence of the rodent homolog of VEGF-A165b has
not yet been identiﬁed.33,34 In addition, the coding sequences for
exon 8 of VEGF-A165a (exon 8a) and VEGF-A165b (exon 8b) are
overlapping, hitherto preventing generation of a VEGF-A165b
knockout mouse model.
Importantly, systemic injections of VEGF-A165b in the type
1 diabetes model also decreased heavy albuminuria and im-
proved some of the histologic features of diabetic nephropathy,
even when treatment was started after the onset of nephropathy,
as might be required in clinical practice. The importance of
defects in glomerular permeability in animal models of early
albuminuric diabetic nephropathy is contested.35,36 These studies
conﬁrm that at least some facets of glomerular structure (endo-
thelial glycocalyx) and permeability (ultraﬁltration coefﬁcient)
are abnormal in early albuminuric diabetic nephropathy and
that reversing these glomerular defects through VEGF-A165b
administration improves glomerular structure/function, albu-
minuria, and histology. This emphasizes the important link be-
tween changes in glomerular function and albuminuria in early
diabetic nephropathy,without excluding the potential importance
of diabetes-induced changes in other parts of the nephron.35–37 In
the type 2 diabetes db/dbmouse model, VEGF-A165b injections
reduced early albuminuria but did not preserve GFR or modify
outcomes when initiated after the onset of nephropathy.
Whether greater VEGF-A165b efﬁcacy in type 1 diabetes models
represents differences in the disease time course,4 pharmacoki-
netics, or validity of the animal model38,39 is not clear. In this
type 2 diabetes model, however, albuminuria was relatively low
in all animals, and after 3 months it regressed rather than pro-
gressed with time.
VEGFR-2 activated by VEGF-A165b was localized to the
endothelium. Decreased glomerular endothelial fenestrations,
as observed here, have also been reported in diabetic humans,
and the possibility of an associated reduction in water perme-
ability was considered.40 In fact, the opposite is the case: Water
permeability is increased in diabetic human glomeruli. More-
over, VEGF-A165b restored normal water permeability and
decreased albuminuria but did not modify fenestral density,
suggesting that an alternative endothelial structure may be
physiologically important and amenable to regeneration in
diabetic nephropathy. The endothelial glycocalyx is a key reg-
ulator of the amount of water and solutes that can cross vessel
walls throughout the microcirculation, as well as regulating
leukocyte adhesion and endothelial responses to mechanical
stimuli.41 The techniques used here conﬁrm42 that glomerular
endothelial glycocalyx can be imaged directly in functioning
glomeruli and coupled with physiologic measurements, com-
plementing techniques involving tissue ﬁxation and indirect
estimates of glycocalyx depth by exclusion. The observed
decrease in glomerular endothelial glycocalyx depth using
two different methods is consistent with albuminuria and
increased water permeability in these two animal models
of diabetic nephropathy, andmatches glomerular permeabil-
ity defects (Figure 10) and systemic endothelial glycocalyx
defects43,44 in diabetic humans. In addition, both acute
and chronic restoration of the endothelial glycocalyx by
VEGF-A165b are also compatible with the observed improve-
ments in both water permeability and albuminuria. The time
course of acute VEGF-A165b–induced changes in glomerular
structure and function match the time course of VEGF-induced
changes in glomerular permeability,15,45,46 and both growth
factor–induced47 and pharmacologic48 restoration of endothelial
glycocalyx indicate that turnover and restoration of endothelial
glycocalyx can be rapid.
Importantly, we believe this is also the ﬁrst demonstration
that long-term restoration of the endothelial glycocalyx is both
feasible and associated with improved long-term outcomes. Be-
cause the endothelial glycocalyx regulatesmechanotransduction,
leukocyte adhesion, and nitric oxide bioavailability,49 all of
which are abnormal in diabetic microvessels, restoring the
endothelial glycocalyx may improve multiple vascular abnor-
malities in diabetes. Identifying the causal nature of the rela-
tionship provides an important direction for future work that
may have implications for vasculoprotection in a broad range
of renal and other diseases.
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In summary, we show here that VEGF-A165b is upregulated
in diabetic patients whose kidney function is well preserved
and that when VEGF-A165b is administered through a variety
of routes, it confers functional and histologic beneﬁt in a series
of animal models of diabetic nephropathy. VEGF-A165b also
effectively restores the endothelial glycocalyx in diabetic
Figure 6. VEGF-A165b reduces apoptosis, decreases glomerular permeability, and acts via VEGFR-2. (A) Apoptosis (caspase-3 activity) was de-
termined in human podocytes in vitro exposed to normal (10 mM) or high (30 mM) cell culture glucose concentrations with or without recombinant
human VEGF-A165b (rhVEGF-A165b). Experiments were done in triplicate. OD, optical density. Error bars, SEM. *P,0.05, one-way ANOVA. (B)
Caspase-3 staining performed on human microvascular endothelial cells exposed to normal (5 mM) or high (30 mM) cell culture glucose con-
centrations in the presence or absence of rhVEGF-A165b. (C) Number of caspase-3–positive cells per high-powered ﬁeld (hpf) compared between
conditions. Experiments were done in quadruplicate. Error bars, SEM. ***P,0.001; "ns" indicates P.0.05; one-way ANOVA for both. (D) Glomerular
water permeability (volume-corrected ultraﬁltration coefﬁcient: LPA/Vi) measured in glomeruli isolated from vehicle-injected nondiabetic (open bar),
and STZ-injected diabetic rats (ﬁlled bars). Glomeruli were incubated for 1 hour in rhVEGF-A165b (1 nM), VEGF-A receptor-2 antagonist ZM323881
(10 mM), pan-VEGF-A receptor blocker PTK787 (100 nM), saline, or combinations thereof before LPA/Vi measurement. Error bars, SEM. Compared
with diabetic: *P,0.05; "ns" indicates P.0.05. Compared with diabetic+rhVEGF-A165b: #P,0.05; "ns1" indicates P.0.05. One-way ANOVA for all.
(E and F) Total and phosphorylated VEGFR-2 in glomeruli of nondiabetic wild-type and nephhVEGF-A165b mice (E) and in glomeruli from STZ-
induced diabetic DBA2J mice treated with vehicle or rhVEGF-A165b (F). Controls without primary antibody are also shown. Scale bars: 20 mm.
VEGFR-2 and phosporylated-VEGFR-2 by area relative to the whole glomerulus quantiﬁed for nondiabetic nephhVEGF-A165b versus litter-
mates (G) and rhVEGF-A165b–treated diabetic mice versus vehicle-treated diabetic mice (H). Error bars, SEM. *P,0.05, one-way ANOVA.
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nephropathy and improves the permeability function of
glomeruli from diabetic humans. VEGF-A165b therefore
appears to exert important protective actions in diabetic
nephropathy.
CONCISE METHODS
All experiments were conducted in accordance with United Kingdom
legislation and local ethical committee approval. Studies on human
kidney tissue were approved by National and Local Research Ethics
Committees (Institutional Ethical Committee, Leiden University
Medical Centre, The Netherlands; South West–Central Bristol Na-
tional Health Service Research Ethics Committee, United Kingdom;
East Midlands–Leicester National Health Service Research Ethics
Committee, United Kingdom), and conducted in accordance with
the Declaration of Helsinki. Human renal cortex samples were
harvested from kidneys offered for transplanta-
tion but were technically unsuitable for im-
plantation from donors without diabetes and
those with early diabetic nephropathy, and for
the late nephropathy group from renal biopsy
specimens harvested for clinical reasons.
Single glomeruli were harvested by differential
sieving for molecular and physiology studies.
Animal studies were approved by University
of Bristol research ethics committee and con-
ducted in accordance with legislation in the
United Kingdom.
Isoform-Speciﬁc RT–Quantitative PCR
Total RNA (RNA) was isolated from human
kidney tissues with Trizol (Invitrogen) and
cleaned up with RNeasy Micro Kit (Qiagen) as
per themanufacturer’s suggestion.RNA, 0.5–1mg,
was reverse transcribed into cDNA with
QuantiTect Reverse Transcription Kit (Qiagen).
cDNA was subjected to quantitative PCR
(qPCR) with forward primer 59- GAGCAAGA-
CAAGAAAATCCC -39 that spans exon 5 and 7
and reverse primer 59- CCTCGGCTTGTCA-
CATCTG -39 spanning exon 7 and 8a to amplify
VEGF-A165a, and with forward primer 59- GAG-
CAAGACAAGAAA ATCCC -39 and reverse
primer 59- GTGAGAGATCTGCAAGTACG -39
spanning exon 7 and 8b to amplify VEGF-A165b.
Each reaction contained 10 ml of SYBR green
master (from Qiagen), 400 nM forward and re-
verse primers, 2 ml plasmid DNA or sample
cDNA, and water to 20 ml. qPCR ampliﬁcation
was initiated at 95°C for 15 minutes, 45 cycles at
95°C for 30 seconds, 60°C for 30 seconds, and 72°C
for 30 seconds, followed by ﬁnal extension at 72°C
for 10 minutes. For VEGF-A165a qPCR, both stan-
dards (1022 to 1026 ng of pcDNA3-VEGF-A165a)
and samples were repeated in duplicate. Ampliﬁcation of known
amounts of plasmid pcDNA3-VEGF-A165a DNA rendered the
formation of a standards curve of DNA amount (x axis) against
cycle threshold (Ct) values (y axis). The amount of VEGF-A165a
mRNA expression was extrapolated by comparing sample Ct
value with the standards curve from plasmid DNA ampliﬁca-
tion. Interference for VEGF-A165a qPCR from VEGF-A165b was
calculated from Ct values obtained from the ampliﬁcation
of VEGF-A165a signal from known concentrations of plasmid
pcDNA3-VEGF-A165b (10
22 to 1024 ng). The interference was,1/1000.
For VEGF-A165b qPCR, a standard curve was formed from ampliﬁ-
cation of known amounts of plasmid pcDNA3-VEGF-A165b DNA
(1022 to 1026 ng). The amount of VEGF-A165b in samples was ex-
trapolated by comparing sample Ct value with the standards curve
from plasmid DNA ampliﬁcation. Interference for VEGF-A165b
qPCR from VEGF-A165 was calculated from Ct values obtained
from the ampliﬁcation of VEGF-A165b signal from known
Figure 7. VEGF-A165b stimulates VEGFR-2 in glomerular endothelial cells in vivo. (A)
Sections of kidney tissue from wild-type and nephhVEGF-A165b mice showing
glomeruli costained for VEGFR-2 (green), and the endothelial cell marker PECAM-1
(red), and overlaid images showing colocalization (yellow). (B) High magniﬁcation of a single
glomerular capillary loop showing VEGFR-2 expression and endothelial cell PECAM-1
colocalize. (C) Sections of kidney tissue from wild-type and nephhVEGF-A165b mice
showing glomeruli costained for VEGFR-2 (green) and the podocyte marker nephrin (red).
(D) High magniﬁcation of a single glomerular capillary loop showing that VEGFR-2 ex-
pression and podocyte nephrin do not colocalize.
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concentrations of plasmid pcDNA3-VEGF-A165 (10
22 to 1024 ng).
The interference was ,1/3000.
ELISA of Pan-VEGF and VEGF-A165b
Proteinwas isolatedfromhumankidney tissuesafterbeinghomogenized
in RIPA buffer (Sigma-Aldrich) and quantiﬁed with Bio-Rad assay.
Pan-VEGF-A and VEGF-A165b detection were followed with the
manufacturer’s suggestion (Duoset human VEGF-A, catalog no.
DY293; R&D Systems, and Duoset human VEGF-A165b, catalog
no. DY3045; R&D Systems). Brieﬂy, 0.08 mg of capture antibody
diluted in 13 PBS (pH, 7.4) was adsorbed onto each well of a
96-well plate (Immulon 2HB; Thermo Fisher Scientiﬁc, Basingstoke,
UK) overnight at room temperature. The plate
was washed three times between each step with
1xPBS-Tween (0.05%). After blocking with
100 ml of 1% BSA in PBS for 1 hour at 37°C,
100 ml of recombinant human VEGF-A165a for
VEGF-AELISA,or recombinanthumanVEGF-A165b
for VEGF-A165b ELISA, diluted in 1%BSA in PBS
(ranging from 62.5 pg/ml to 4 ng/ml) or protein
samples were added to eachwell. After incubation
for 1 hour at 37°C with shaking and three washes,
100 ml of detection antibody at 0.05 mg/ml was
added to each well, and the plate was left for
1 hour at 37°C with shaking. Next, 100 ml of
streptavidin-horseradish peroxidase (R&D Sys-
tems) at 1:200 dilution in 1% BSA in PBS was
added, the plate was left at room temperature for
20 minutes, and 100 ml of O-phenylenediamine
dihydrochloride solution per well (Substrate
reagent pack DY-999; R&D Systems) was added,
protected from light and incubated for 20minutes
at room temperature. The reaction was stopped
with 50ml/well 1MH2SO4, and absorbance was
read immediately in the Opsys MR 96 well
plate reader at 492 nm, with control reading
at 460 nm.
Animal Studies
Transgenic mice were obtained from in-house
colonies. Adultmalemice were used for all mouse
studies, and wild-type littermate controls were
used for comparison. Details of the transgenic
strategies for the nephhVEGF-A165b and pod-rTta:
TetO-mVEGF-A164a mice are provided in detail
elsewhere.15,20 pod-rTta:TetO-mVEGF-A164a
mice were generated by crossing podocin-rTtA
andTetO-VEGF-A164amice supplied by Professor
Susan Quaggin with permission from Jeffrey
Kopp (National Institute of Diabetes and Di-
gestive and Kidney Diseases, National Institutes
of Health, Bethesda, MD) and Jeff Whitsett (Chil-
dren’s Hospital Medical Center, Cincinnati,
OH). Overexpression of human VEGF-A165b in
podocytes (nephhVEGF-A165b) was constitutive.
Overexpression of murine VEGF-A164a (
mVEGF-A164a) in podocytes
in pod-rTta:TetO-mVEGF-A164amicewas induced by adding doxycycline
(2mg/ml) in light-protected drinking water containing 5%w/v sucrose
that was changed twice per week.
nephhVEGF-A165b were generated on a C57Bl6 background, and
diabetes induction with a moderate-dose STZ regimen (100 mg/kg
for 3 consecutive days) was therefore required to elicit nephropathy in
the littermate controls. After crossing nephhVEGF-A165b mice with
pod-rTta:TetO-mVEGF-A164a mice (mixed strain background), the
low-dose Animal Models of Diabetic Complications Consortium
(AMDCC) STZ protocol (50 mg/kg for 5 consecutive days) was
used. DBA2J mice were also treated with the low-dose AMDCC
Figure 8. VEGF-A165b restores the glomerular endothelial glycocalyx in early STZ-
induced diabetic nephropathy. Six weeks after STZ (or buffer) injections to induce
diabetes (or normoglycemia) in DBA2J mice, mice received biweekly intraperitoneal
injections of vehicle or rhVEGF-A165b for 4 weeks. Animals were cardiac perfusion ﬁxed
and renal cortices were processed for transmission electron microscopy. (A) Glomeruli
were imaged at low magniﬁcation, the glomerular capillary wall at higher magniﬁcation,
and endothelial cell surface at high magniﬁcation using transmission electron microscopy.
e-glx, endothelial glycocalyx; ec, endothelial cell; fen, endothelial fenestra; gbm,
glomerular basement membrane; gc, glomerular capillary; pfp, podocyte foot process;
us, urinary space. (B) Endothelial fenestral density and (C) glycocalyx depth covering
the glomerular endothelial cell surface quantiﬁed in electron microscopic images
from vehicle-treated nondiabetic, vehicle-treated diabetic, and rhVEGF-A165b–treated
diabetic animals. Error bars, SEM. n=3 mice per group. *P,0.05; "ns" indicates P.0.05;
one-way ANOVA for both.
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streptozotocin protocol50 to induce diabetes and associatednephropathy.
db/db mice (BKS.Cg-+Leprdb/+Leprdb/OlaHsd) were purchased from
Harlan Laboratories, UK, and fed a standard rodent diet. Diabetes was
induced in rats with a single intravenous injection of STZ (45 mg/kg).51
All animals were fasted for 4–6 hours before administration of STZ.
Recombinant human VEGF-A165b (
rhVEGF-A165b) for intraperitoneal
injection was generated as previously described,30 and was administered
after conﬁrmation of two consecutive readings of hyperglycemia
(.16 mmol).
Bodyweight and blood glucose (ACCU-CHEKAviva, Roche)were
monitored weekly after STZ administration in mice, 1 week after
administration of STZ in rats, and starting from 6 weeks of age in db/db
mice. Urine samples were collected by overnight housing in metabolic
cages.Urinaryalbuminwasquantiﬁedwithalbumin
ELISA (Bethyl Laboratories, Inc.), and creatinine
was measured using an enzymatic spectrophoto-
metric assay (Konelab T-Series 981845; Thermo
Fisher Scientiﬁc). Urinary albumin-to-creatinine
ratio was calculated as the quotient of albumin
concentration and creatinine concentration. Cre-
atinine clearance was calculated from the volume
of urine produced in a timed collection, creatinine
concentration in the same sample, and creatinine
concentration in blood harvested at culling. GFR
was determined with FITC-inulin injection in
conscious mice before culling, in accordance with
the AMDCC protocol.52
Kidney cortex samples harvested immedi-
ately postmortem were ﬂash frozen, and 5- to
10-mmsectionswere cut using a rotarymicrotome.
Sections were mounted onto glass slides and
stained with hematoxylin and eosin using stan-
dard techniques. Images were captured using a
DCN-100 digital imaging system (Nikon In-
struments, Surrey, UK). Glomerular area was
calculated from the glomerular outline. Sepa-
rate sections were stained with 0.5% periodic
acid, Schiff reagent, and Mayer hematoxylin.
The proportion of the glomerulus positive for
periodic acid-Schiff stain was determined ac-
cording to AMDCC protocols using Adobe
Photoshop software.
For standard transmission electron micros-
copy, animals were ﬂushed by transcardiac
perfusion with Ringer solution and then ﬁxed
with 2.5% glutaraldehyde (61% Alcian blue for
endothelial glycocalyx labeling), and small
pieces (0.5- to 1-mm diameter) of kidney cortex
studies were rapidly excised and ﬁxed in 2.5%
glutaraldehyde in 0.1M cacodylate buffer (4°C),
washed in 0.1 M cacodylate buffer, postﬁxed in
1% osmium tetroxide, and washed in distilled
water. Tissues were ethanol-dehydrated and
embedded in an Araldite (Agar Scientiﬁc). Sec-
tions 50 to 100 nm thick were stained with 3%
(aqueous) uranyl acetate and Reynolds lead citrate solution. Digital
micrographs were taken on a Phillips 100CS microscope or Tecnai
T12 microscope at3940,31250, and36200. Images of the glomer-
ular capillary wall were blinded, and detailed measurements were
taken randomly using a predeﬁned algorithm using Adobe Photoshop.
A ﬁxed digital grid was superimposed over the electron micrograph,
and glycocalyx depth was measured at points of intersection between
these ﬁxed gridlines and the image of the glomerular capillary
wall. In total, 1696 randomized measurements of glycocalyx depth
in 179 glomerular capillaries from nine animals across the three ex-
perimental groups were made using this algorithm by a blinded ob-
server, and all analyses were completed before unblinding. Endothelial
fenestrae were also counted in the same images, and fenestral density
Figure 9. VEGF-A165b restores glomerular endothelial glycocalyx acutely in diabetic
rat glomeruli. Kidneys were perfused in vivo with cell membrane label (R18; red) and
glycocalyx label (Alexa Fluor-488–wheat germ agglutinin lectin; green), and then
glomeruli were isolated and treated with vehicle or VEGF-A165b for 1 hour (exactly as
per physiology experiments) before imaging with confocal microscopy. (A) whole
glomerulus; scale bar: 20 mm. (B) Glomerular capillaries (gc) with endothelial cell (ec)
bodies; scale bar: 5 mm. (C) High-magniﬁcation image (scale bar: 1 mm) of a vehicle-
treated glomerular capillary from a healthy animal, demonstrating glomerular endo-
thelial glycocalyx (GLX) lining luminal surface of endothelial cell body. gcw, glomerular
capillary wall. (D) High-magniﬁcation image (scale bar: 1 mm) of a vehicle-treated
glomerular capillary from a diabetic animal. Note absent glomerular endothelial
glycocalyx (absent GLX) lining the luminal surface of endothelial cell body. (E) High-
magniﬁcation image (scale bar: 1mm) of a VEGF-A165b–treated glomerular capillary
from a diabetic animal. Note restoration of glomerular endothelial glycocalyx. (F)
Mean6SEM glomerular endothelial glycocalyx depth in ﬁve glomeruli in each of three
animals per group. *P,0.05, one-way ANOVA.
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was calculated as the percentage of glomerular basement membrane
ﬁltration surface covered by endothelial fenestrae.
Kidney samples for immunoﬂuorescence studies were formalin-
ﬁxed and embedded in wax. Five-micrometer sections were mounted
onto glass slides and left to dry overnight at 37°C. Sections were then
dewaxed and rehydrated before staining using anti-VEGFR-2 1:50
(Cell Signaling Technology) and anti–P-VEGFR-2 (Y-951) 10 mg/ml
(Santa Cruz Biotechnology). Primary antibodies were left to incubate
at 4°C overnight before incubating with the appropriate ﬂuorescent
secondary. Before imaging, the sections were also stained for Hoechst
and then viewed on the ﬂuorescent microscope. The area of staining for
VEGFR-2/p-VEGFR-2 was normalized to glomerular area to calculate
the percentage glomerular area covered by staining. For colocalization
studies, fresh-frozen 5-mm sections were embedded in optimal cutting
temperature compound. Sections were ﬁxed in 4% paraformaldehyde
before costaining with anti–VEGFR-2 1:50 (Cell Signaling Technology)
and either antinephrin 10 mg/ml (2B Scientiﬁc/Acris) or anti–PECAM-1
10 mg/ml (Abcam, Inc.). Z-stack confocal microscopy imaging was used
to assess colocalization.
For confocal imaging of the glomerular endothelial glycocalyx in
functioning glomeruli avoiding ﬁxation artifact, kidneys were perfused
in vivo with R18 (cell membrane label) and Alexa Fluor-488–labeled
wheat germ agglutinin lectin (labels N-acetyl glucosamine [a compo-
nent of heparan sulfate and hyaluronan glycosaminoglycans] and
N-acetyl neuraminic acid [a major sialic acid present on the endothe-
lial cell surface] glycosaminoglycans on the endothelial cell surface).
Glomeruli were isolated by differential sieving, incubated in vehicle
or 1 nM rhVEGF-A165b to match glomerular physiology measure-
ments, and imaged with confocal microscopy. Glomerular endothelial
glycocalyx depth was measured as the distance between peak ﬂuores-
cent signal from the cell membrane over the endothelial cell body, and
from the overlying glomerular endothelial glycocalyx; measurements were
taken over the endothelial cell body to eliminate
interference from labeled glycosaminoglycans
within the glomerular basement membrane
beneath attenuated and fenestrated endothelial
areas elsewhere in the glomerular capillary wall.
Cell Culture Studies
Caspase 3 activity wasmeasured in conditionally
immortalized human podocytes53 using the
CaspACE assay kit (Promega) according to the
manufacturer’s indications. Brieﬂy, cells were
lysed and incubated with the Asp-Glu-Val-
Asp-p-Nitroaniline (DEVD-pNA) colorimetric
substrate, which, upon cleavage by caspase 3, re-
sults in free pNA. Free pNAproduces a yellow color
monitored at 405 nm and proportional to the
caspase activity. Absorption at 405 nm is normal-
ized on the amount of total protein in samples.
Human umbilical vein endothelial cells were
isolated from umbilical cords obtained with
consent under ethical approval and cultured (up
to passage 6) until they reached 80% conﬂuence.
These cells were then treated with normal EBM2
media (5 mM glucose; Lonza) or with media that contained an
additional 30 mM glucose for hyperglycemic conditions. Osmotic
control was performed replacing 30 mM glucose with 30 mM
mannitol. Drug groups used combinations of the following: vehicle
(PBS; n=4 per group), 2.5 nM VEGF-A165b (n=4 per group), and/or
200 nMPTK787 (vandetanib54). The number of activated caspase-3 cells
was totaled from ﬁve random ﬁelds of view per well. These were in-
cubated for 24 hours and were processed for polyclonal rabbit activated
caspase-3 (apoptotic cell death marker, 1 in 500; New England Biolabs)
staining and Hoechst staining. Negative controls were performed
with no primary antibody or cleaved caspase-3 blocking peptide
(New England Biolabs).
Glomerular Permeability Assay
Glomeruli were harvested from mouse, rat, or human cortical renal
tissue by differential sieving, and the glomerular ultraﬁltration
coefﬁcient (LPA: hydraulic conductivity-area product) was measured
using a validated oncometric assay as previously described.45 In brief,
individual glomeruli were mounted on a holding pipette within a
ﬂow-controlled observation chamber by gentle aspiration. The perifusate
surrounding the glomerulus was rapidly exchanged from incubating
solution (1% BSA in HEPES Ringer solution) to 8% BSA-HEPES
Ringer solution, thereby increasing the oncotic pressure outside the
glomerular capillary wall relative to the glomerular capillary lumen.
The consequent ﬂux of water out of the glomerular capillaries results
in a rapid reduction in glomerular volume, which was recorded con-
tinuously on video camera and analyzed ofﬂine using Fiji software55
with in-house macros (developed by K. Arkill). Linear regression anal-
ysis was used to calculate the initial (,0.1 second) rate of reduction of
glomerular volume (JV) in response to the applied oncotic pressure
gradient (DP), the quotient of which describes glomerular ultraﬁltra-
tion coefﬁcient (LPA). For incubation studies, glomeruli were incubated
Figure 10. VEGF-A165b normalizes permeability of diabetic mouse, rat, and human
glomeruli. (A) Glomeruli were harvested from 6 diabetic (STZ-injected) wild-type, 4
nondiabetic wild-type, and 8 diabetic (STZ) nephhVEGF-A165b mice (102 glomeruli); from
3 diabetic (STZ) and 3 nondiabetic rats (74 glomeruli); and from untransplantable kidneys
from 3 nondiabetic and 3 diabetic human kidney donors (54 glomeruli). Glomerular water
permeability (volume-corrected ultraﬁltration coefﬁcient: LPA/Vi) was measured in in-
dividual glomeruli following exposure to constitutively overexpressed hVEGF-A165b
(mice) or 1-hour incubation in vehicle or rhVEGF-A165b (rat and human glomeruli). Error
bars, SEM. *P,0.05; "ns" indicates P.0.05; one-way ANOVA for both. (B) Glomerular
LPA/Vi was measured twice in 3 diabetic human glomeruli, before (black) and after (blue)
1-hour incubation in rhVEGF-A165b. *P,0.05, paired t test.
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for 1 hour with appropriate agents: 1 nM rhVEGF-A165b30; 10 mM ZM
323881 (Calbiochem; EMD Millipore); 100 nM PTK 787 (Novartis
Pharma, Basel, Switzerland). Human glomeruli are signiﬁcantly larger
than rodent glomeruli (P,0.05) (Supplemental Figure 1A) and there-
fore present a greater surface area (A) for ﬂuid exchange across the
glomerular capillary wall. Glomeruli harvested from healthy humans
had substantially higher ultraﬁltration coefﬁcient (LPA) values than rats
andmice (P,0.05) (Supplemental Figure 1B). When corrected for glo-
merular volume (Vi), human and rat glomeruli had identical normal-
ized ultraﬁltration coefﬁcient values (LPA/Vi) (Supplemental Figure 1C)
but had signiﬁcantly lowerLPA/Vi thanmouse glomeruli (bothP,0.05)
(Supplemental Figure 1C).
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